ASLAN Pharmaceuticals(ASLN) - 2022 Q4 - Annual Report

https://reportify-1252068037.cos.apbeijing.myqcloud.com/media/production/ASLN7 Exhibit 99.1 PRESS RELEASE ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023 - Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024 - Expected ...